Gazette No 21, Tuesday 15 October 2024
Contents
- Agricultural chemical products and approved labels – 1
- Veterinary chemical products and approved labels – 15
- Approved active constituents – 19
- Licensing of veterinary chemical manufacturers – 22
APVMA decision to immediately cancel all products with chlorthal dimethyl
The Australian Pesticides and Veterinary Medicines Authority (APVMA) has cancelled all 12 products containing the herbicide chlorthal dimethyl.
Special Gazette, 10 October 2024
Contents
- Notice of cancellation under section 45A(1)(b) of the Agricultural and Veterinary Chemicals Code – chlorthal dimethyl chemical product registrations – 1
- Attachment A – Brief statement of reasons for the decision to cancel chlorthal dimethyl chemical product registrations under section 35A of the Agvet Code – 3
APVMA cancels all products containing chlorthal dimethyl
The Australian Pesticides and Veterinary Medicines Authority (APVMA) has cancelled the registration and use of all products containing chlorthal dimethyl, al
Gazette No 20, Tuesday 1 October 2024
Contents
- Agricultural chemical products and approved labels – 1
- Veterinary chemical products and approved labels – 8
- Approved active constituents – 13
- New active constituent – Famoxadone – 15
- Application for registration of a new product, Zorvec Encantia Fungicide containing famoxadone and oxathiapiprolin – 18
- New veterinary chemical products containing a new veterinary active constituent – 20
- Agvet chemical voluntary recall: Neptra Otic Solution for Dogs – 27
- Agvet chemical voluntary recall: NITROFURAZONE
Senvelgo 15 mg/mL Oral Solution for Cats containing velagliflozin L-proline monohydrate
The APVMA is considering an application for approval of the new active constituent, velagliflozin L-proline monohydrate and the registration of the product, Senvelgo 15 mg/mL Oral Solution for Cats, is indicated for the reduction of hyperglycaemia and improvement in associated clinical signs in otherwise healthy cats with non-insulin dependent diabetes mellitus.
We invite comments from 1 October 2024 to 29 October 2024 on whether approval of the active constituent and registration of the product should be granted.